Novartis、FDA修正Imatinib標(biāo)簽以反映心臟毒性風(fēng)險

Novartis、FDA修正Imatinib標(biāo)簽以反映心臟毒性風(fēng)險

October19,2006--Novartis和美國食品及藥物管理局(FDA)發(fā)一封信給健康照護(hù)專業(yè)人士，信中提到白血病藥物imatinib(Gleevec,Glivec)的嚴(yán)重郁血性心臟衰竭和左心室功能不全之風(fēng)險，并將之在藥品標(biāo)簽上新；該信結(jié)論指出，任何有心臟病或心衰竭風(fēng)險的人，應(yīng)被謹(jǐn)慎監(jiān)控使用此藥，若有心衰竭癥狀出現(xiàn)應(yīng)被及時治療。

FDA和該公司對此標(biāo)簽的改變，是因為自然醫(yī)學(xué)(Nature Medicine)期刊今年稍早的一篇報導(dǎo)，提到此藥在10位慢性骨髓性白血病患之心臟毒性副作用的研究。

信中提到，我們藉此提供您有關(guān)Gleevec和自然醫(yī)學(xué)線上版的一篇近來受到媒體關(guān)注的文章的訊息；信中，Novartis腫瘤部門之美國臨床發(fā)展與醫(yī)療事務(wù)副總裁John Hohneker醫(yī)師指出，因此藥所致之心臟毒性副作用是屬于NYHA class1且仍有正常左心室射出分率，相關(guān)資料可在自然醫(yī)學(xué)網(wǎng)站上獲得；些病患數(shù)本來就有類似狀況，如高血壓、糖尿病和冠狀動脈疾病。

信中指出，因為自然醫(yī)學(xué)期刊研究的出版，Novartis 回顧了所有現(xiàn)有的臨床試驗和其他報告的資料；信件的結(jié)論是，雖然心臟不良反應(yīng)事件不常見，但嚴(yán)重郁血性心臟衰竭和左心室功能不全仍偶被報告，因此我們建議任何有心臟病或心衰竭風(fēng)險的人，應(yīng)被謹(jǐn)慎監(jiān)控使用此藥，若有心衰竭癥狀出現(xiàn)應(yīng)被及時評估與治療。

信中指出，標(biāo)簽的警語已經(jīng)修改納入此一建議，相關(guān)資料也可在FDA的MedWatch 網(wǎng)站看到。

Novartis,FDA Revise Imatinib Label to Reflect Cardiotoxicity Risk

By

Medscape Medical News

October19,2006— Novartis and the US Food and Drug Administration(FDA)have sent a letter to healthcare professionals to clarify the risk of severe congestive heart failure and left ventricular dysfunction in patients taking the leukemia drug imatinib(Gleevec,Glivec)and to update them on changes to the drug label.The letter concludes that anyone with known heart disease or risk factors for heart failure should be monitored carefully and treated if heart failure symptoms arise.

The move on the part of the agency and drug maker comes after a study appeared in Nature Medicine earlier this year reporting cardiotoxic side effects of the drug in10patients with chronic myelogenous leukemia.

"We are writing to provide you information regarding Gleevec and an article published online in Nature Medicine,which recently received media coverage," the letter reads.In it,John Hohneker,MD,vice president,US clinical development and medical affairs in the oncology division at Novartis,notes that supplemental data available on the Nature Medicine Web site indicates that all of the patients who suffered cardiotoxic side effects from the drug had NYHA class1functioning and normal left ventricular ejection fractions."Most of these patients had preexisting conditions,including hypertension,diabetes,and coronary artery disease," Hohneker notes.

Since the publication of the Nature Medicine study,Novartis has reviewed all available data from clinical trials and other reports,the letter notes.It concludes:"While cardiac events remain uncommon,severe congestive heart failure and left ventricular dysfunction have occasionally been reported.As such we believe any patients with known cardiac disease or risk factors for cardiac failure should be monitored carefully,and any patient with symptoms consistent with cardiac failure should be evaluated and treated."

The precautions section of the label have been modified to include this recommendation,the letter notes.The information also appears on the FDA's MedWatch Web site.

Nat Med.2006;12:908-916.

沈陽哪里可以買到瑞士諾華格列衛(wèi)（甲磺酸伊馬替尼片）？規(guī)格、價格是多少？

諾華的一半大醫(yī)院都有賣的，價格兩萬五左右一個月。
買三贈九。
每天吃兩次，每次吃兩粒。
直接找大醫(yī)院的醫(yī)生購買就可以，當(dāng)然，前提是必須是要慢粒等適應(yīng)癥才行。
有什么白血病方面的問題，可以加入白血病群，與里面的醫(yī)生及病友多交流。
祝愿病人健康，快樂。加油

本文地址:http://www.mcys1996.com/zhongyizatan/32360.html.

聲明： 我們致力于保護(hù)作者版權(quán)，注重分享，被刊用文章因無法核實真實出處，未能及時與作者取得聯(lián)系，或有版權(quán)異議的，請聯(lián)系管理員，我們會立即處理，本站部分文字與圖片資源來自于網(wǎng)絡(luò)，轉(zhuǎn)載是出于傳遞更多信息之目的,若有來源標(biāo)注錯誤或侵犯了您的合法權(quán)益，請立即通知我們(管理員郵箱：douchuanxin@foxmail.com)，情況屬實，我們會第一時間予以刪除，并同時向您表示歉意,謝謝!

上一篇: Deferasirox可能與腎功衰竭···

下一篇: 先靈葆雅CEO稱文迪雅危機(jī)可累及其他···